In humans B‐symptoms refer to systemic symptoms of lymphoma such as fever, weight loss, and night sweats and influence the prognosis of patients. In canine lymphoma, substage B is used to describe any clinical sign observed. Aim of the retrospective study was to compare the prognostic value of substage B with B‐symptoms to predict treatment response and survival in canine nodal diffuse large B‐cell lymphoma. Affected dogs treated with CHOP chemotherapy between 2008 and 2019 were included. B‐symptoms were defined by weight loss greater than 10% of normal weight, fever and the occurrence of unexplained resting tachypnoea substituted human night sweats. Substage B was defined as any symptoms but lymphadenopathy. Fifty‐five cases were included. B‐symptoms were present in 20/55 (36%) and substage B in 40/55 (74%) patients. No significant associations between B‐symptoms or substage B and weight, sex, breed, WHO stage and lymphoma grade were found. Treatment response was negatively associated with both substage B (P = .02) and B‐symptoms (P = .001). B‐symptoms significantly decreased progression free survival (PFS) (95 vs 330 days, P = .001) and lymphoma specific survival (LSS) (160 vs 462 days, P = .001). Data showed that B‐symptoms might be a more reliable prognostic indicator than substage B in canine nodal diffuse large B‐cell lymphoma. Prospective studies assessing B‐symptoms in a larger cohort of patients and in other common lymphoma types are warranted. The abstract was presented at the fourth meeting of the European Canine Lymphoma Network Group in Lugano, 22 June 2019 and published in the proceeding of the meeting on the page 26.

中文翻译：

---

B 症状是否比犬淋巴结弥漫性大 B 细胞淋巴瘤亚期更可靠的预后指标

在人类中，B 症状是指淋巴瘤的全身症状，如发热、体重减轻和盗汗，并影响患者的预后。在犬淋巴瘤中，B 亚期用于描述观察到的任何临床体征。回顾性研究的目的是比较 B 亚期与 B 症状的预后价值，以预测犬淋巴结弥漫性大 B 细胞淋巴瘤的治疗反应和存活率。包括在 2008 年至 2019 年间接受 CHOP 化疗的患病犬。B 症状的定义是体重减轻超过正常体重的 10%、发烧和发生不明原因的静息呼吸急促代替人类盗汗。B亚期定义为除淋巴结病外的任何症状。共纳入 55 例。20/55 (36%) 患者出现 B 症状，40/55 (74%) 患者出现 B 亚期症状。未发现 B 症状或 B 亚期与体重、性别、品种、WHO 分期和淋巴瘤分级之间存在显着关联。治疗反应与 B 亚期（P = .02 ) 和 B 症状 ( P = .001 )。B 症状显着降低无进展生存期 (PFS)（95 天与 330 天，P = .001）和淋巴瘤特异性生存期（LSS）（160 天与 462 天，P = .001）。数据显示，在犬淋巴结弥漫性大 B 细胞淋巴瘤中，B 症状可能是比 B 亚期更可靠的预后指标。在更大的患者队列和其他常见淋巴瘤类型中评估 B 症状的前瞻性研究是有必要的。摘要已于 2019 年 6 月 22 日在卢加诺举行的欧洲犬淋巴瘤网络小组第四次会议上提交，并在第 26 页的会议纪要中发表。